Allergy Diagnostics & Therapeutics Market: as biologics push the ceiling of what allergic disease control looks like, every patient a biologic manages profitably now depends on a diagnostic test confirming the right sensitisation first, so the two halves of this market are becoming a single prescribing pathway rather than two separate purchases, and competitive advantage is moving toward companies that own both ends of that pathway rather than either end alone.

The global allergy diagnostics and therapeutics market size was USD 36.8 Billion in 2025 and is expected to register a revenue CAGR of 8.2% during the forecast period. Market revenue growth is driven by factors such as the scale of allergic disease across inhaled, food, and drug allergen categories, the commercial expansion of biologic therapeutics for moderate-to-severe allergic disease, and label expansions that widen the eligible treatment population. The first driving factor is the scale of allergic disease relative to the population receiving both diagnosis and treatment. The World Allergy Organization estimates that allergic diseases affect 20 to 30% of the world population, and the United States alone has an estimated food allergy prevalence of approximately 10.8% of adults, confirming a patient population whose management requires both diagnostic testing and therapeutic intervention. The second driving factor is the commercial scale reached by biologic therapeutics for allergic disease. Biologic therapeutics including dupilumab and omalizumab collectively account for approximately 38% of total 2025 market revenue, reflecting the scale of atopic dermatitis, severe asthma, and chronic rhinosinusitis treatment programmes now running at hospital allergy and dermatology departments globally. The third driving factor is regulatory label expansion widening the treated-eligible population for existing therapeutics. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single approved biologic accumulates additional indications on the same molecule over its lifecycle, which converts one initial regulatory approval into a widening set of billable patient populations without a new drug development programme. Once a biologic earns its first allergic-disease indication, each additional approved indication such as a new age group or a new related inflammatory condition adds a new eligible patient population to the same manufacturing and commercial infrastructure, so revenue per approved molecule compounds as its indication set widens around the same mechanism of action. As a result, demand and revenue share are concentrating around biologics with the broadest indication sets, and the forecast tilts toward multi-indication anti-inflammatory biologics rather than single-indication allergy therapeutics. For instance, in February 2026, Sanofi and Regeneron's Dupixent received FDA approval as the first and only treatment for allergic fungal rhinosinusitis in patients aged 6 and older, the ninth distinct FDA-approved indication for the same molecule and one of a widening set of type 2 inflammatory conditions it now carries without any new drug development programme. These are some of the key factors driving revenue growth of the market.

Because dupilumab and omalizumab carry annual treatment costs of USD 30,000 to USD 40,000 per patient at US list pricing, payer prior authorisation requirements confine biologic eligibility to patients with documented moderate-to-severe disease who have already failed conventional corticosteroid and antihistamine therapy, so a meaningful share of the addressable allergic disease population never reaches biologic treatment regardless of clinical need.

Underdiagnosis in primary care is a second constraint, because the JAMA Internal Medicine finding that a majority of penicillin-labelled patients have never been formally tested shows that even basic confirmatory allergy testing is inconsistently ordered, which limits the population correctly identified as candidates for either immunotherapy or biologic treatment.

Biologic manufacturing capacity is a third constraint, since monoclonal antibody production requires specialised biologics manufacturing infrastructure that cannot scale as quickly as small-molecule generic production, so new biologic entrants face a multi-year capacity build before they can compete at volume with established anti-IgE and anti-IL-4/IL-13 franchises.

These factors substantially limit allergy diagnostics and therapeutics market growth over the forecast period.

The clearest driver of demand is the commercial scale biologic therapeutics have reached in allergic disease, converting a category once managed with antihistamines and corticosteroids into a targeted mechanism-of-action treatment category. Anti-IgE and anti-IL-4/IL-13 biologics work by blocking specific inflammatory signalling pathways rather than suppressing immune activity broadly, and because that mechanism generalises across multiple type 2 inflammatory conditions, a single approved molecule can expand into new indications without a new drug development programme each time. Biologic therapeutics collectively account for approximately 38% of total 2025 market revenue, and Sanofi and Regeneron jointly reported Dupixent global net sales of USD 14.97 Billion in FY2024, confirming the commercial scale this mechanism-targeted approach has reached. In February 2026, Sanofi and Regeneron's Dupixent received FDA approval as the first treatment for allergic fungal rhinosinusitis in patients aged 6 and older, its ninth distinct FDA-approved indication. The effect on the market is that biologic revenue growth increasingly comes from label expansion on existing approved molecules rather than from new molecule launches. These are some of the key factors driving revenue growth of the market.

The second driver is the systematic expansion of allergen immunotherapy product labels from adults into progressively younger paediatric populations. The immunological rationale for allergen immunotherapy is strongest earlier in a patient's disease course, so extending a sublingual immunotherapy label to younger children creates a new prescribing population precisely where the treatment's disease-modifying potential is greatest, rather than only capturing patients after their allergic disease has already progressed. ALK-Abelló is the global leader in sublingual immunotherapy tablet products through its GRAZAX grass pollen and ACARIZAX house dust mite tablets, giving it the commercial infrastructure to support each successive paediatric label expansion. In February 2025, ALK-Abelló received FDA approval expanding its ODACTRA house dust mite immunotherapy tablet label to children aged 5 to 11, extending sublingual immunotherapy into the paediatric allergy management market. The effect on the market is a widening prescribing base for sublingual immunotherapy among paediatric allergists who previously had fewer approved treatment options for younger patients. These are some of the key factors driving revenue growth of the market.

Dupixent's February 2026 approval for allergic fungal rhinosinusitis is its ninth distinct FDA-approved indication. Each additional indication adds a new eligible patient population to the same manufacturing and commercial infrastructure already in place.

The third driver is the early entry of interchangeable biosimilars into the anti-IgE biologic class, which lowers the net cost of biologic treatment for payers willing to substitute. Biosimilar competition works by giving payers a lower-cost interchangeable alternative to the original branded biologic, so once an interchangeable anti-IgE biosimilar reaches the market, payers gain negotiating leverage that can loosen prior authorisation criteria previously set to ration access to the higher-cost branded product. In March 2025, Celltrion received FDA approval for an interchangeable omalizumab biosimilar, referencing Xolair, and giving payers their first interchangeable substitution option in the anti-IgE biologic class for allergic disease indications. The effect on the market is downward pressure on the effective net price of anti-IgE treatment, which should modestly widen the payer-eligible treated population over the forecast period even as branded list prices remain high. These are some of the key factors driving revenue growth of the market.

However, the allergy diagnostics and therapeutics market faces severe adoption constraints from the high cost of biologic therapeutics and the persistent underdiagnosis of allergic disease in primary care.

Because dupilumab and omalizumab carry annual treatment costs of USD 30,000 to USD 40,000 per patient at US list pricing, payer prior authorisation requirements confine biologic eligibility to patients with documented moderate-to-severe disease who have already failed conventional corticosteroid and antihistamine therapy, so a meaningful share of the addressable allergic disease population never reaches biologic treatment even where clinical need is well established.

Underdiagnosis in primary care compounds this, because the JAMA Internal Medicine finding that a majority of penicillin-labelled patients have never been formally tested shows that basic confirmatory allergy testing is inconsistently ordered, which limits the population correctly identified as candidates for either immunotherapy or biologic treatment before cost even becomes a factor.

Biologics manufacturing capacity is the third constraint, since monoclonal antibody production requires specialised infrastructure that cannot scale as quickly as small-molecule generic manufacturing, so new biosimilar entrants face a multi-year capacity build before they can compete at volume with established anti-IgE and anti-IL-4/IL-13 franchises.

These factors substantially limit allergy diagnostics and therapeutics market growth over the forecast period.

Based on product type, the global allergy diagnostics and therapeutics market is segmented into diagnostic instruments and consumables, allergen immunotherapy, and biologic therapeutics. Biologic therapeutics hold the largest revenue share, because anti-IgE and anti-IL-4/IL-13 franchises now carry list prices of USD 30,000 to USD 40,000 per patient annually across multiple approved indications, which suits a market where per-patient revenue is set largely by treatment mechanism rather than by testing volume. Allergen immunotherapy remains established for patients seeking disease-modifying rather than symptom-suppressing treatment and is cheaper per course than biologic therapy, but it cannot match the rapid symptom control that drives biologic prescribing in severe disease. Diagnostic instruments and consumables are expected to register the fastest revenue growth rate in the global allergy diagnostics and therapeutics market over the forecast period, driven by the diagnostic testing volume required to confirm biologic and immunotherapy eligibility, which is why Thermo Fisher's ImmunoCAP platform continues to expand its component-resolved testing menu alongside biologic label growth.

In vitro blood tests test type is expected to account for a significantly large revenue share in the global allergy diagnostics and therapeutics market during the forecast period

Based on test type, the global allergy diagnostics and therapeutics market is segmented into in vitro blood tests, in vivo skin tests, provocation and challenge tests, and molecular component-resolved diagnostics. In vitro blood tests hold the largest revenue share, because specific IgE quantification is the default confirmatory step before both immunotherapy and biologic prescribing decisions, which suits a market where testing and treatment are now procured along the same clinical pathway. Molecular component-resolved diagnostics are expected to register the fastest revenue growth rate in the global allergy diagnostics and therapeutics market over the forecast period, driven by payers increasingly requiring component-level confirmation before authorising immunotherapy, which is why ALK-Abelló's telehealth-enabled testing partnership pairs diagnostic access directly with its immunotherapy prescribing pathway.

Based on allergen type, the global allergy diagnostics and therapeutics market is segmented into inhaled allergens, food allergens, and drug allergens and other contact allergens. Food allergens hold the largest revenue share, because a 2019 JAMA Network Open study estimated food allergy prevalence at approximately 10.8% of US adults, a population whose management increasingly spans both diagnostic confirmation and biologic treatment such as omalizumab's food allergy indication. Drug allergens are expected to register the fastest revenue growth rate in the global allergy diagnostics and therapeutics market over the forecast period, driven by hospital antimicrobial stewardship programmes funding penicillin-specific IgE testing at scale, which is why ALK-Abelló and reference laboratory networks are expanding telehealth-enabled drug allergy testing access.

Based on regional analysis, the allergy diagnostics and therapeutics market in North America accounted for largest revenue share in 2025. The United States leads because its biologic payer infrastructure and the commercial presence of Sanofi, Regeneron, Genentech, and Thermo Fisher Scientific concentrate both prescribing volume and testing infrastructure in one market, and because the CDC's reported 8% US asthma prevalence sustains a large treated population across both diagnostic and therapeutic channels. Sanofi and Regeneron jointly reported Dupixent global net sales of USD 14.97 Billion in FY2024, a majority of which is concentrated in the US market, anchoring North America's leadership position. The concentration of biologic regulatory approvals in the country also means new allergy indications are typically approved in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. ALK-Abelló, headquartered in Copenhagen, maintains its primary commercial base in Europe through its GRAZAX and ACARIZAX sublingual immunotherapy tablets, and European national health systems' reimbursement processes for both immunotherapy and biologic therapeutics shape adoption pacing differently across member states. The result is steady rather than rapid growth, shaped more by national reimbursement negotiation timelines than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising urban allergic disease prevalence and expanding biologic therapeutic access as regulatory approval timelines shorten. Japan is the earlier-launch market for new biologic indications in the region, which leaves more room for growth than in the already biologic-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private payer and hospital networks driving early biologic and immunotherapy adoption among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the diagnostic reagents and cold-chain biologic logistics that Latin American distributors depend on, an effect expected to run through 2026 and slow combined diagnostics and therapeutics adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for combined allergy diagnostics and therapeutics adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist and biologic reimbursement infrastructure needed to support this market at scale.